Abstract: The present invention is directed to a cyclic polypeptide having ubiquitin binding affinity (KD) of 0.1-100 nM. Further provided are methods for reducing deubiquitination activity of a cell, and for treating cancer in a subject in need thereof.
Type:
Grant
Filed:
November 8, 2022
Date of Patent:
September 10, 2024
Assignees:
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, THE UNIVERSITY OF TOKYO
Inventors:
Ashraf Brik, Mickal Nawatha, Hiroaki Suga, Joseph Rogers
Abstract: A composition comprises one or more trimesic acid derivatives of Formula (I) in which R1, R2, and R3 are independently selected from the group consisting of alkyl groups. A polymer composition comprises a composition as described above and a polyolefin polymer. The polymer compositions containing a trimesic acid derivative of Formula (I) exhibit very low haze levels and minimal extraction of the trimesic acid derivative.
Type:
Grant
Filed:
October 2, 2023
Date of Patent:
September 10, 2024
Assignee:
Milliken & Company
Inventors:
Daniel Kremer, Hans-Werner Schmidt, Paul Smith, John David Anderson, Suchitra Datta, Keith Keller, Nathan Mehl, Walter Scrivens
Abstract: The present invention concerns a block copolymer having at least one oligo- or polysaccharide block and at least one elastin-like polypeptide block, wherein said block copolymer comprises at least one repetitive unit having the following formula (I): wherein R? is the side chain of a natural or synthetic amino acid other than proline and derivatives thereof.
Type:
Grant
Filed:
September 25, 2019
Date of Patent:
September 10, 2024
Assignees:
INSTITUT POLYTECHNIQUE DE BORDEAUX, Centre national de la recherche scientifique, UNIVERSITÉ DE BORDEAUX
Inventors:
Sébastien Lecommandoux, Elisabeth Garanger, Xiao Ye
Abstract: There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).
Type:
Grant
Filed:
June 8, 2023
Date of Patent:
September 3, 2024
Assignee:
Zealand Pharma A/S
Inventors:
Mohammed Monzur Morshed, Sai Kumar Chakka, Jennifer L. Hickey, Manuel Perez Vazquez, Andrew Roughton, Adam Paul Kafal, Narendrakumar B. Patel
Abstract: Disclosed are cationic lipids which are compounds of Formula (I), (II), (III), (IV), (V), or (VI). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Type:
Grant
Filed:
May 23, 2019
Date of Patent:
September 3, 2024
Assignee:
TRANSLATE BIO, INC.
Inventors:
Yi Zhang, Shrirang Karve, Frank DeRosa, Michael Heartlein
Abstract: Described herein are peptides that can be used to treat pain or increase pain sensitivity in subject in need of treatment. Additionally, peptides of the present disclosure can be administered with an analgesic agent and/or anesthetic agent. Peptides of the present disclosure are suitable for use when a subject in need of treatment has an injury, a chronic disease, a chronic inflammation, Morton's neuroma, operative/post-operative pain, or a combination thereof.
Type:
Grant
Filed:
September 29, 2022
Date of Patent:
September 3, 2024
Assignee:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Abstract: The invention relates to a process for the preparation of Melphalan (4-[bis(2-chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: —N(CH2CH2OS(O)nO?)2, wherein n is 1 or 2 followed by conversion of the —N(CH2CH2OS(O)nO?)2 group into a —N(CH2CH2Cl)2 group. The invention also provides novel intermediates useful for the preparation of Melphalan.
Type:
Grant
Filed:
May 19, 2023
Date of Patent:
September 3, 2024
Assignee:
Indena S.P.A.
Inventors:
Pietro Allegrini, Andrea Bonetti, Marco Molinari, Andrea Gambini
Abstract: A method for producing a carbodiimide compound, comprising a carbodiimide production step of reacting an aliphatic tertiary isocyanate compound (A) in the presence of an inorganic alkali metal compound (B) and at least one of a phase transfer catalyst (C), a compound (D-1) represented by general formula (2-1), and a compound (D-2) represented by general formula (2-2).
Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.
Type:
Grant
Filed:
March 7, 2022
Date of Patent:
August 27, 2024
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
Abstract: Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
Type:
Grant
Filed:
May 21, 2021
Date of Patent:
August 20, 2024
Assignees:
The Children's Medical Center
Corporation, The General Hospital Corporation
Inventors:
Umut Ozcan, Joseph Majzoub, Ralph Mazitschek
Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
Type:
Grant
Filed:
December 19, 2022
Date of Patent:
August 20, 2024
Assignee:
Purdue Pharmaceutical Products L.P.
Inventors:
Thomas Jorg Mehrling, Enrique Maria Ocio
Abstract: Methods and compositions for treating aging-related diseases as well as muscle recovery, prevention of muscle degeneration, and maintenance of muscle are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing disease.
Abstract: Disclosed herein are engineered bacteria that manufacture biofilms from bacterial amyloid structures. These biofilms and biofilm matrices are capable of generating fibrous proteinaceous networks and being used as 3D-printing inks.
Abstract: The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.
Abstract: In various aspects and embodiments the invention provides compositions and methods for facilitating cell penetration of a cargo molecule. In another aspect, the invention provides a method of preventing viral infection in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of a polypeptide comprising a cell-penetrating peptide and a retromer binding site.
Type:
Grant
Filed:
May 24, 2019
Date of Patent:
August 13, 2024
Assignee:
YALE UNIVERSITY
Inventors:
Daniel DiMaio, Pengwei Zhang, Gabriel Monteiro Da Silva, Weiya Bai
Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).
Type:
Grant
Filed:
March 25, 2022
Date of Patent:
August 6, 2024
Assignee:
CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC
Abstract: The present invention relates to compositions comprising daptomycin and at least one amino acid, methods of providing such compositions and the uses thereof.
Type:
Grant
Filed:
August 2, 2023
Date of Patent:
August 6, 2024
Assignee:
Xellia Pharmaceuticals APS
Inventors:
Anita Bevetek Mocnik, Stipica Tomic, Barbara Fumic
Abstract: The present disclosure relates to compositions, methods of preparation of the compositions, and methods including administration of said compositions for the prevention of neurological damage associated with cerebral ischemia.
Type:
Grant
Filed:
November 16, 2021
Date of Patent:
August 6, 2024
Assignee:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP) or at least one cysteine protease (CP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease or at least one cysteine protease (CP), and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease or at least one cysteine protease (CP) in a variety of therapeutic, diagnostic and prophylactic indications.